8.3 Emergency Escalation & Status Epilepticus Management

8.3 Emergency Escalation & Status Epilepticus Management

Status Epilepticus (SE) is a life-threatening neurological emergency defined by the failure of normal physiological mechanisms responsible for seizure termination, or the initiation of mechanisms that lead to abnormally prolonged seizure activity. In the Epilepsy Monitoring Unit (EMU) and Intensive Care Unit (ICU), long-term monitoring technologists work on the front line of seizure detection. Technologists must immediately recognize prolonged electrographic and clinical seizures, execute standardized emergency notifications, provide critical bedside airway and physical support, and assist the medical team in escalating therapeutic interventions according to evidence-based resuscitation algorithms.

---

1. Operational Definition & Pathophysiological Timeline

The International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) define status epilepticus using a dual-time-point conceptual framework: Time $t_1$ (the time to initiate emergent treatment) and Time $t_2$ (the time beyond which continuous seizure activity produces long-term neuronal injury and systemic morbidity).

+-----------------------------------------------------------------------------+
|              ILAE / AES STATUS EPILEPTICUS OPERATIONAL TIMELINE             |
|                                                                             |
|   SEIZURE ONSET (0 Minutes)                                                 |
|        |                                                                    |
|        v                                                                    |
|   TIME t1: OPERATIONAL DEFINITION (Initiate Emergent Pharmacotherapy)       |
|   - Generalized Convulsive Status Epilepticus (GCSE): 5 MINUTES             |
|   - Focal Status Epilepticus with Impaired Awareness: 10 MINUTES            |
|   - Absence Status Epilepticus: 10 - 15 MINUTES                             |
|        |                                                                    |
|        v  [Ongoing Excitotoxicity, GABA Internalization, NMDA Upregulation] |
|        |                                                                    |
|   TIME t2: PERMANENT DAMAGE THRESHOLD (Neuronal Injury & Systemic Crisis)   |
|   - Generalized Convulsive Status Epilepticus (GCSE): 30 MINUTES            |
|   - Focal Status Epilepticus: > 60 MINUTES                                  |
+-----------------------------------------------------------------------------+

Molecular & Systemic Pathophysiology

As a continuous convulsive seizure progresses from minutes into hours, profound molecular and systemic derangements occur:

+-----------------------------------------------------------------------------+
|                 MOLECULAR EVOLUTION OF REFRACTORY STATUS                    |
|                                                                             |
|   CONTINUOUS SEIZURE ACTIVITY (> 5 - 10 Minutes)                            |
|        |                                                                    |
|        +-----------------------------------+                                |
|        |                                   |                                |
|        v                                   v                                |
|   GABA-A RECEPTOR ENDOCYTOSIS         NMDA / AMPA RECEPTOR RECRUITMENT      |
|   - Synaptic GABAA receptors are      - Excitatory glutamate receptors move |
|     internalized into endosomes       from intracellular pool to synapse    |
|   - Loss of postsynaptic GABA sites   - Massive calcium influx & excitotox. |
|   - RESULTS IN BENZODIAZEPINE         - RESULTS IN SUSTAINED SEIZURE        |
|     PHARMACORESISTANCE!                 PROPAGATION & CELL DEATH!           |
+-----------------------------------------------------------------------------+

• Receptor Trafficking & Pharmacoresistance: Within 10 to 30 minutes of continuous seizing, postsynaptic $\text{GABA}_A$ receptors undergo endocytosis and internalization, reducing the number of functional inhibitory targets on the neuronal surface. Consequently, first-line benzodiazepines lose efficacy rapidly as seizure duration extends. Simultaneously, excitatory NMDA and AMPA glutamate receptors are recruited to the synaptic membrane, creating an escalating state of self-sustaining hyperexcitability.
• Systemic Metabolic Decompensation: Prolonged GCSE leads to severe systemic crisis: hyperthermia, severe lactic acidosis (pH < 7.0), rhabdomyolysis, myoglobinuric acute kidney injury, hyperkalemia, cardiac arrhythmias, autonomic hyperstimulation followed by cardiovascular collapse, neurogenic pulmonary edema, and blood-brain barrier breakdown.

---

2. Three-Phase Status Epilepticus Management Algorithm

Medical management of status epilepticus follows a standardized, three-phase escalation protocol based on guidelines from the American Epilepsy Society (AES) and the Established Status Epilepticus Treatment Trial (ESETT).

+-----------------------------------------------------------------------------+
|           THREE-PHASE STATUS EPILEPTICUS ESCALATION ALGORITHM               |
|                                                                             |
|   [PHASE 1: EMERGENT INITIAL THERAPY (0 - 5 to 10 Minutes)]                 |
|   - Assess Airway, Breathing, Circulation (ABCs), High-flow O2 via NRB      |
|   - Rapid bedside capillary blood glucose (If <60 mg/dL: D50W + Thiamine)   |
|   - FIRST-LINE BENZODIAZEPINES:                                             |
|     * IV Lorazepam: 0.1 mg/kg (Max 4 mg slow IV push; repeat once at 5-10m) |
|     * IM Midazolam: 10 mg IM (>40 kg) or 5 mg IM (13-40 kg) if no IV access |
|     * Rectal Diazepam: 0.2 mg/kg (Max 20 mg) if IV/IM unavailable           |
|                                                                             |
|   [PHASE 2: URGENT CONTROL / ESTABLISHED STATUS (20 - 40 Minutes)]          |
|   - Indicated if SE persists despite adequate Phase 1 benzodiazepines       |
|   - SECOND-LINE IV NON-SEDATING ASMs (ESETT Regimens):                      |
|     * IV Levetiracetam: 60 mg/kg IV (Max 4500 mg over 10-15 min)            |
|     * IV Fosphenytoin: 20 mg PE/kg IV (Max 1500 mg PE, <= 150 mg PE/min)    |
|     * IV Valproate Sodium: 40 mg/kg IV (Max 3000 mg over 10 min)           |
|                                                                             |
|   [PHASE 3: REFRACTORY STATUS EPILEPTICUS / RSE (> 40 - 60 Minutes)]        |
|   - Indicated if SE persists despite Phase 1 and Phase 2 therapy            |
|   - Critical Care: Endotracheal intubation, mechanical ventilation, ICU line|
|   - THIRD-LINE CONTINUOUS ANESTHETIC INFUSIONS:                             |
|     * IV Midazolam: Bolus 0.2 mg/kg -> Infusion 0.05 - 2.0 mg/kg/hr         |
|     * IV Propofol: Bolus 1 - 2 mg/kg -> Infusion 30 - 100 mcg/kg/min        |
|     * IV Ketamine: Bolus 1 - 2 mg/kg -> Infusion 1 - 5 mg/kg/hr             |
|     * IV Pentobarbital: Bolus 5 mg/kg -> Infusion 1 - 5 mg/kg/hr            |
|   - cEEG Target: Titrate to complete electrographic cessation or BURST      |
|     SUPPRESSION pattern (10-15 sec suppression) for 24-48 hours.            |
+-----------------------------------------------------------------------------+

Phase 1: Emergent Initial Therapy (0–5 to 10 Minutes)

• Supportive Resuscitation: Immediate evaluation of Airway, Breathing, and Circulation (ABCs). Apply high-flow oxygen via non-rebreather mask (10–15 L/min), attach continuous pulse oximetry, and initiate continuous ECG telemetry.
• Bedside Glucose Check: Perform an immediate fingerstick blood glucose check. If hypoglycemic (<60 mg/dL), administer 50 mL of 50% Dextrose (D50W) IV accompanied by 100 mg of IV Thiamine in adults to prevent acute Wernicke encephalopathy.
• First-Line Benzodiazepine Selection:
  • IV Lorazepam (Ativan): 0.1 mg/kg IV (standard adult dose: 4 mg slow IV push over 2 minutes; may repeat once after 5–10 minutes if seizures persist). First-line choice when established IV access is present due to high efficacy and prolonged redistribution half-life in brain tissue.
  • IM Midazolam (Versed): 10 mg IM for patients weighing >40 kg (5 mg IM for 13–40 kg). Demonstrated in the RAMPART clinical trial to be superior to IV lorazepam when IV access is not already established, due to rapid intramuscular absorption without vascular delay.
  • Rectal Diazepam (Diastat): 0.2 mg/kg (maximum 20 mg) or intranasal midazolam/diazepam when neither IV nor IM routes are immediately accessible.

Phase 2: Urgent Control / Established Status (20–40 Minutes)

If seizures continue despite adequate first-line benzodiazepine administration, second-line IV non-sedating ASMs must be administered rapidly as continuous IV infusions. The landmark ESETT (Established Status Epilepticus Treatment Trial) established that levetiracetam, fosphenytoin, and valproate sodium possess equivalent clinical efficacy (~45–50% seizure termination at 60 minutes) and safety profiles:

1. IV Levetiracetam (Keppra): 60 mg/kg IV (maximum dose: 4500 mg), infused over 10 to 15 minutes. Excellent safety profile with negligible cardiorespiratory depression and zero cytochrome P450 interactions.
2. IV Fosphenytoin (Cerebyx): 20 mg PE/kg IV (maximum dose: 1500 mg PE [Phenytoin Equivalents]).
   • Infusion Rate Safety Limit: Infusion rate must NEVER exceed 150 mg PE/minute in adults (or 2 mg PE/kg/min in children).
   • Advantages over Phenytoin: Fosphenytoin is a water-soluble prodrug that does not require propylene glycol solvent. It eliminates the severe risks of vehicle-induced tissue necrosis ("purple glove syndrome") and severe chemical phlebitis.
   • Cardiovascular Monitoring: Continuous ECG and blood pressure monitoring are mandatory during infusion. Infusion rates exceeding 150 mg PE/min can trigger severe rate-related hypotension, complete AV block, and lethal ventricular arrhythmias (Black Box Warning).
3. IV Valproate Sodium (Depacon): 40 mg/kg IV (maximum dose: 3000 mg), infused over 10 minutes.
   • Contraindications: Strictly contraindicated in patients with known or suspected mitochondrial disorders (POLG mutations) due to the risk of fatal hepatic failure, acute liver disease, and active pregnancy.

Phase 3: Refractory Status Epilepticus (RSE) & Super-Refractory Status (SRSE)

• Definition of RSE: Seizures that persist clinically or electrographically despite adequate doses of a first-line benzodiazepine and a second-line IV ASM (typically lasting >40–60 minutes).
• Definition of SRSE: Status epilepticus that continues or recurs 24 hours or more after the initiation of continuous intravenous anesthetic therapy, including cases where seizures recur upon anesthetic reduction.
• Critical Care Interventions: Immediate endotracheal intubation, mechanical ventilation, placement of a central venous catheter, and invasive arterial line monitoring to manage severe vasodilation and hypotension.
• Third-Line Continuous Anesthetic Infusions:
  • Midazolam Infusion: Loading dose of 0.2 mg/kg IV bolus, followed by continuous infusion of 0.05 to 2.0 mg/kg/hr.
  • Propofol (Diprivan) Infusion: Loading dose of 1 to 2 mg/kg IV bolus, followed by continuous infusion of 30 to 100 mcg/kg/min (2–5 mg/kg/hr).
    • Propofol Infusion Syndrome (PRIS): A potentially lethal complication characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, hepatomegaly, renal failure, and refractory myocardial failure. Risk escalates dramatically when propofol doses exceed 4 to 5 mg/kg/hr or when infusions last longer than 48 hours.
  • Ketamine Infusion: NMDA receptor antagonist (1–2 mg/kg bolus, then 1–5 mg/kg/hr). Highly effective in late refractory status because it targets upregulated NMDA receptors when GABA receptors are internalized.
  • Pentobarbital / Thiopental Coma: High-potency barbiturate infusion. Causes profound myocardial depression and peripheral vasodilation; continuous vasopressor support (e.g., norepinephrine) is almost universally required.
• ICU cEEG Titration Endpoint: Continuous ICU EEG monitoring is deployed to titrate anesthetic infusions to a predefined electrophysiological target: either complete electrographic seizure suppression or a burst suppression pattern (typically 10 to 15 seconds of inter-burst isoelectric suppression between bursts) maintained continuously for 24 to 48 hours before controlled weaning.

---

3. EMU Technologist Emergency Protocol & Bedside Duties

When a prolonged seizure or status epilepticus occurs in the EMU, the neurodiagnostic technologist executes a coordinated sequence of technical, safety, and clinical actions:

+-----------------------------------------------------------------------------+
|                 EMU TECHNOLOGIST EMERGENCY ACTION TIMELINE                  |
|                                                                             |
|   T = 0:00 (SEIZURE ONSET)                                                  |
|   - Hit event button / timestamp digital EEG acquisition log                |
|   - Ensure camera is centered, zoomed, and patient fully visible            |
|   - Turn room lights fully ON; pull back bedding to visualize extremities   |
|                                                                             |
|   T = 0:30 - 1:00 (BEDSIDE SAFETY & AIRWAY)                                 |
|   - Enter patient room immediately; do NOT leave patient unattended         |
|   - Position patient in LATERAL DECUBITUS (recovery position)               |
|   - NEVER place any object, bite block, or fingers into the mouth!          |
|   - Clear hard, sharp objects away from head and limbs                      |
|                                                                             |
|   T = 2:00 - 3:00 (ICTAL ASSESSMENT & OXYGENATION)                          |
|   - Apply high-flow oxygen (10-15 L/min NRB mask)                           |
|   - Perform standardized ictal testing (memory words, language, motor)      |
|   - Suction oral cavity gently AFTER tonic/clonic phase if secretions pool  |
|                                                                             |
|   T = 3:00 - 5:00 (EMERGENCY ESCALATION / TIME t1)                          |
|   - Push emergency nurse call / activate Rapid Response Team (RRT)          |
|   - Alert attending epileptologist; prepare bedside rescue IV lorazepam     |
|   - Annotate medication delivery and exact clinical/EEG cessation times     |
+-----------------------------------------------------------------------------+

Detailed Technologist Bedside Actions

1. EEG Time-Stamping & Annotation: Immediately place a digital marker on the acquisition recording. Annotate clinical semiology milestones (e.g., initial head deviation, tonic stiffening, synchronized clonic jerking, stertorous respirations, post-ictal generalized attenuation).
2. Visual & Environmental Management: Ensure the video camera is focused on the patient. Remove sheets and blankets to allow full visualization of limb motor movements, automatisms, and autonomic signs. Ensure room lights are on.
3. Airway Protection & Lateral Positioning: Roll the patient onto their side into the lateral decubitus position (recovery position). This allows the tongue to fall forward and facilitates passive drainage of saliva, vomitus, and secretions, preventing life-threatening pulmonary aspiration.
4. Absolute Prohibition of Oral Foreign Objects: NEVER insert any object, bite block, tongue blade, airway, or finger into the patient's mouth during an active convulsion. Forcing objects into the mouth causes severe dental fractures, tongue lacerations, laryngospasm, airway obstruction, and technologist injury.
5. Standardized Ictal & Post-Ictal Testing: As soon as feasible without compromising safety, assess the patient's level of awareness:
   • Present memory registration words (e.g., "Blue Velvet", "Apple 74").
   • Test language comprehension (e.g., "Touch your nose", "Point to the window").
   • Assess motor strength and bilateral hand grasp.
   • Test post-ictal recall and orientation (person, place, time).

---

4. Status Epilepticus Pharmacotherapy Summary Matrix

+-------------------------------------------------------------------------------------------------+
|                       STATUS EPILEPTICUS PHARMACOTHERAPY MATRIX                                 |
|                                                                                                 |
|   PHASE / AGENT    DOSE & ROUTE               ADMINISTRATION RATE      KEY SAFETY WARNINGS      |
|   ---------------  -------------------------  -----------------------  -----------------------  |
|   PHASE 1:                                                                                      |
|   IV Lorazepam     0.1 mg/kg (Max 4 mg)       Slow IV push over 2 min  Respiratory depression;  |
|                                                                        hypotension              |
|   IM Midazolam     10 mg IM (>40 kg)          Intramuscular injection  Rapid onset; RAMPART trial|
|                    5 mg IM (13-40 kg)                                  choice if no IV access   |
|                                                                                                 |
|   PHASE 2:                                                                                      |
|   IV Levetiracetam 60 mg/kg (Max 4500 mg)     Infuse over 10-15 min    Minimal cardiorespiratory|
|                                                                        depression; very safe    |
|   IV Fosphenytoin  20 mg PE/kg (Max 1500 mgPE) <= 150 mg PE/min        BLACK BOX: Hypotension & |
|                                                                        arrhythmias if >150/min  |
|   IV Valproate Sod.40 mg/kg (Max 3000 mg)     Infuse over 10 min       Fatal hepatic failure in |
|                                                                        POLG / mitochondrial dis.|
|                                                                                                 |
|   PHASE 3 (RSE):                                                                                |
|   Continuous       Midazolam, Propofol,       Continuous ICU infusion  Requires intubation,     |
|   Anesthetics      Ketamine, Pentobarbital    titrated to cEEG         arterial line, burst-supp|
+-------------------------------------------------------------------------------------------------+

---

5. Clinical Traps & High-Yield Exam Pitfalls

[!CAUTION] Critical Clinical Traps in Status Management:

• Trap 1: Underdosing Benzodiazepines: The single most common error in Phase 1 status epilepticus management is administering inadequate subtherapeutic doses of benzodiazepines (e.g., giving 1 mg of IV lorazepam to an 80 kg adult instead of the guideline-recommended 4 mg [0.1 mg/kg]). Underdosing fails to terminate status while allowing GABA-A receptors to internalize, rendering subsequent doses ineffective.
• Trap 2: Exceeding Fosphenytoin Infusion Rates: Administering fosphenytoin at rates >150 mg PE/min can trigger lethal bradycardia, complete heart block, and profound vasodilation-induced shock. Always ensure continuous cardiac rhythm monitoring.
• Trap 3: Missing Electrographic NCSE after Convulsion Cessation: In up to 20% to 30% of patients whose motor convulsions terminate following Phase 1 or 2 therapy, electrographic seizures persist in the brain (electroclinical dissociation). Continuous cEEG is mandatory to confirm electrographic cessation.